Discovery of small molecule inhibitors of protein-protein interactions using combined ligand and target score normalization

Journal of Chemical Information and Modeling

Volumn 49, Issue 12, 2009, Pages 2708-2717

  Casey, Fergal P ^a   Pihan, Emilie ^a   Shields, Denis C ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

EFFICIENCY; PEPTIDES;

ANTI-APOPTOTIC PROTEIN; EXPERIMENTAL DEVELOPMENT; NEGATIVELY CHARGED; NUCLEAR RECEPTORS; PROTEIN-PROTEIN INTERACTIONS; SCORE NORMALIZATION; SMALL MOLECULE INHIBITOR; TARGET DIMENSIONS;

LIGANDS;

LIGAND; PEPTIDE; PROTEIN;

ARTICLE; BINDING SITE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DEVELOPMENT; DRUG EFFECT; HUMAN; METABOLISM; METHODOLOGY; MOLECULAR LIBRARY; PROTEIN BINDING; PROTEIN TERTIARY STRUCTURE;

BINDING SITES; DRUG DISCOVERY; HUMANS; LIGANDS; MODELS, MOLECULAR; PEPTIDES; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; PROTEINS; SMALL MOLECULE LIBRARIES;

EID: 73349090936     PISSN: 15499596     EISSN: 1549960X     Source Type: Journal    
DOI: 10.1021/ci900294x     Document Type: Article

References (58)

1. Vassilev, L. T.; et al. In Vivo Activation of the P53 Pathway by Small-Molecule Antagonists of Mdm2. Science 2004, 303 (5659), 844-848.
2. Arkin, M. R.; Wells, J. A. Small-Molecule Inhibitors of Protein-Protein Interactions: 'Progressing towards the Dream. Nat. Rev. Drug Discovery 2004, 3, 301-317.
3. Reixach, N.; Adamski-Werner, S. L.; Kelly, J. W.; Koziol, J.; Buxbaum, J. N. Cell Based Screening of Inhibitors of Transthyretin Aggregation, Biochem. Biophys. Res. Commun. 2006, 348 (3), 889-897.
4. Sun, H. Pharmacophore-Based Virtual Screening. Curr. Med. Chem. 2008, 15 (10), 1018-1024.
5. Toba, S.; Srinivasan, J.; Maynard, A. J.; Sutter, J. Using Pharmacophore Models To Gain Insight Into Structural Binding and Virtual Screening: An Application Study with Cdk2 and Human Dhfr. J. Chem. Inf. Model. 2006, 46, 728-735.
6. Parathasarathi, L.; Casey, F.; Stein, A.; Aloy, P.; Shields, D. C. Approved Drug Mimics of Short Peptide Ligands from Protein Interaction Motifs. J. Chem. Inf. Model. 2008, 48, 1943-1948.
7. Puntervoll, P.; et al. Elm Server: A New Resource for Investigating Short. Functional Sites in Modular Eukaryotic Proteins. Nucleic Acids Res. 2003, 31 (13), 3625-3630.
8. Stein, A.; Aloy, P. Contextual Specificity in Peptide-Mediated Protein Interactions. PloS ONE 2008, 3 (7), e2524.
9. Wishart, D. S.; et al. DrugBank: A Comprehensive Resource for in Silico Drug Discovery and Exploration. Nucleic Acids Res. 2006, 34, D668-672.
10. Chemical Computing Group Inc. Molecular Operating Environment, Version 2008.08. Montreal, Canada.
11. Huey, R.; Morris, G. M.; Olson, A. J.; Goodsell, D. S. A Semiempirical Free Energy Force Field with Charge-Based Devolvation. J. Comput. Chem. 2007, 28, 1145-1152.
12. Morris, G. M.; Goodsell, D. S.; Halliday, R. S.; Huey, R.; Hart, W. E.; Belew, R. K.; Olson, A. J. Automated Docking Using a Lamarckian Genetic Algorithm and Empirical Binding Free Energy Function. J. Comput. Chem. 1998, 19, 1639-1662.
13. Vigers, G. P.; Rizzi, J. P. Multiple Active Site Corrections for Docking and Virtual Screening. J. Med. Chem. 2004, 47, 80-89.
14. Wallace, A. C; Laskowski, R. A.; Thornton, J. M. Ligplot: A Program To Generate Schematic Diagrams of Protein-Ligand Interactions. Protein Eng. 1995, 8, 127-134.
15. Brasher, S. V.; Smith, B. O.; Fogh, R. H.; Nietlispach, D.; Thiru, A.; Nielsen, P. R.; Broadhurst, R. W.; Ball, L. J.; Murzina, N. V.; Laue, E. D. The Structure of Mouse Hp1 Suggests a Unique Mode of Single Peptide Recognition by the Shadow Chromo Domain Dimer. EMBO J. 2000, 19 (7), 1587-1597.
16. Li, M.; Monis, G. M.; Lee, T.; Laco, G. S.; Wong, C. H.; Olson, A. J.; Elder, J. H.; Wlodawer, A.; Gustchina, A. Structural Studies of FIV and HIV-1 Proteases Complexed with an Efficient Inhibitor of FIV Protease, Proteins 2000, 38, 29-40. (Pubitemid 30020600)
17. Loughlin, W. A.; Tyndall, J. D. A.; Glenn, M. P.; Fairlie, D. P. BetaStrand Mimetics. Chem. Rev. 2004, 104, 6085-6117.
18. Norwood, L. E,.; et al. A Requirement for Dimerization of Hpl. in Suppression of Breast Cancer Invasion. J. Biol. Chem. 2006, 281, 18668-18676.
19. Wintjens, R.; Wieruszeski, J. M.; Drobecq, H.; Rousselot-Pailley, P.; Buée, L.; Lippens, G.; Landrieu, I. 1H NMR Study on the Binding of Pinl Trp-Trp Domain with. Phosphothreonine Peptides. J. Biol. Chem. 2001, 276 (27), 25150-25156. (Pubitemid 37412996)
20. Huang, X.; Poy, F.; Zhang, R.; Joachimiak, A.; Sudol, M.; Eck, M. J. Structure of a WW Domain Containing Fragment of Dystrophin in Complex with Beta-Dystroglycan. Nat. Struct. Biol. 2000, 7, 634-638.
21. +)Atpase Activity in Heart Muscle after Chronic Treatment with Digitoxin or Potassium. Deficient Diet. Eur. J. Pharmacol. 1976, 37 (1), 189-191.
22. Saito, K.; Ohkura, H.; Kashima, T.; Tanaka, H. Enhanced Sensitivity to Digoxin in Dystrophic Mice. Jpn. Heart J. 1984, 25, 765-777.
23. Heyck, H.; Laudahn, G.; Luders, C. .T.; Muller-Stephann, H.; SchmidtPeter, P. Anabolic Steroids and Digitoxin in the Treatment of Progressive Muscular Dystrophy. Acta Paediatrica 1965, 54 (3), 205-221.
24. Lopez-Lazaro, M.; Pastor, N.; Azrak, S. S.; Ayuso, M. J.; Austin, C. A.; Cortes, F. Digitoxin Inhibits the Growth of Cancer Cell Lines at Concentrations Commonly Found in Cardiac Patients. J. Nat. Prod 2005, 68(11), 1642-1645. (Pubitemid 41789573)
25. Anderson, S. M.; et al. Etoposide-Induced Activation of C-Jun N-Terminal Kinase (Jnk) Correlates with Drug-Induced Apoptosis in Salivary Gland Acinar Cells Cell Death Differentiation 1999,6 (5)454-462.
26. Chang, N.-S.; et al. Molecular Mechanisms Underlying Woxl Activation during Apoptotic and Stress Responses. Biochem. Pharmacol. 2003, 66 (8), 1347-1354. (Pubitemid 38379588)
27. Yang, Q.; et al. Cardiac Glycosides Inhibit. TNF-α/NF-κB Signaling by Blocking Recruitment of Tnf Receptor-Associated Death Domain to the Tnf Receptor. Proc. Natl. Acad. Sci. U.S.A. 2005, 102 (27), 9631-9636.
28. Allen, R. T.; Cluck, M. W.; Agrawal, D. K. Mechanisms Controlling Cellular Suicide: Role of Bcl-2 and Caspases. Cell. Mol. Life. Sci. 1998, 54, 427-445.
29. Oltersdorf, T.; et al. An Inhibitor of Bcl-2 Family Proteins Induces Regression of Solid Tumours. Nature 2005, 435, 677-681.
30. Shuker, S. B.; Hajduk, P. J.; Meadows, R. P.; Fesik, S. W. Discovering High-Affinity Ligands for Proteins: Sar by NMR. Science 1996, 274, 1531-11153
31. Horwitz, K. B.; Jackson, T. A.; Bain, D. L.; Richer, J. K.; Takimoto, G. S.; Tung, L. Nuclear Receptor Coactivators and Corepressors. Mol. Endocrinol. 1996, 10, 1167-1177.
32. Hashimoto, Y.; Miyachi, H. Nuclear Receptor Antagonists Designed Based on the Helix-Folding Inhibition Hypothesis, Bioorg. Med. Chem. 2005, 13 (17), 5080-5093. (Pubitemid 41039968)
33. Jensen, E. V.; Khan, S. A. A Two-Site Model For Antiestrogen Action. Mechanisms of Ageing and Development 2004, 125 (10), 679-682.
34. Wang, Y.; Chirgadze, N. Y.; Briggs, S. L.; Khan, S.; Jensen, E. V.; Burris, T. P. A Second Binding Site for Hydroxytamoxifen within the Coactivator-Binding Groove of Estrogen Receptor Beta. Proc. Natl. Acad. Sci. U.S.A. 2005, 103 (26), 9908-9911.
35. Mizwicki, M. T.; et al. Identification of An Alternative Ligand-Binding Pocket in. the Nuclear Vitamin D Receptor and Its Functional Importance in 1Alpha,25(OH)2-Vitamin D3 Signaling. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 12876-12881.
36. Kuenzli, S.; Tran, C; Saurat, J. H. Retinoid Receptors in. Inflammatory Responses: A Potential Target for Pharmacology. Current Drug Targets; Inflammation and Allergy 2004, 3 (4), 355-1300
37. Farrehi, P. M.; Zhu, Y.; Fay, W. P. An Analysis of Mechanisms Underlying the Antifibrinolytic Properties of Radiographic Contrast Agents. J. Thrombosis and Thombolysis 2001, 12 (3), 273-281.
38. Mendoza, N.; Fong, S., Marsters, J.; Koeppen, H; Schwall, R.; Wickramasinghe, D. Selective Cyclin-Dependent Kinase2/Cyclin A Antagonists That Differ from Atp Site Inhibitors Block Tumor Growth. Cancer Res. 2003, 63, 1020-1024.
39. de Boer, S. F.; Lesourd, M; Mocaer, E.; Koolhaas, J. M. Selective Antiaggressive Effects of Alnespirone in Resident-Intruder Test Are Mediated via 5-Hydroxytryptamine1A Receptors: A Comparative Pharmacological Study with. 8-Hydroxy-2-dipropylaminotetralin, Ipsapirone, Buspirone, Eltoprazine, and Way-100635. J. Pharmacol. Exp. Ther. 1999, 288 (3), 1125-1133.
40. Buolamwini, J. K.; Addo, J.; Kamath, S.; Paul, S.; Mason, D.; Ores, M. Small Molecule Antagonists of the Mdm2 Oncoprotein as Anticancer Agents. Curr. Cancer Drug targets 2005, 5, 57-68.
41. Morrison, N. E.; Marley, G. M. Clofazimine Binding Studies with Deoxyribonucleic Acid.Int J. Lepr Other Mycobact Dis 1976, 44 (4), 475-481.
42. Pourgholami, M. H.; Lu, Y.; Wang, L.; Stephens, R. W.; Morris, D. L. Regression of Novikoff Rat Hepatocellular Carcinoma Following Locoregional Administration of a Novel Formulation of Clofazimine in Lipiodol. Cancer Lett. 2004, 207 (1), 37-47.
43. Van Rensburg, C. E.; Joone, G. K.; O'Sullivan, J. F. Clofazimine and B4121 Sensitize an Intrinsically Resistant Human Colon Cancer Cell Line to P-Glycoprotein Substrates. Oncol. Ren. 2000, 7 (1), 193-195.
44. Van Rensburg, C. E. J.; Van. Staden, A. M.; Anderson, R. The Riminophenazine Agents Clofazimine and B669 Inhibit the Proliferation of Cancer Cell Lines in Vitro by Phospholipase A2-Mediated Oxidative and Nonoxidative Mechanisms. Cancer Res. 1993, 53, 318-323. (Pubitemid 23031843)
45. Corthesy-Theulaz, I.; Pauloin, A.; Pfeffer, S. R. Cytoplasmic Dynein Participates in the Centrosomal Localization of the Golgi Complex. J. Cell Boil. 1992, 118 (6), 1333-1345.
46. Jung, Y.; Kim, H.; Min, S. H.; Rhee, S. G.; Jeong, W. Dynein Light Chain Lc8 Negatively Regulates NF-κB through the Redox-Dependent Interaction with IκBα. J. Biol. Chem. 2008, 283 (35), 23863-23871.
47. Crepieux, P.; et al. IκBα Physically Interacts with a CytoskeletonAssociated Protein through Its Signal Response Domain. Mol. Cell. Biol. 1997, 17 (12), 7375-7385.
48. Widen, C.; Gustafsson, J. A.; Wikstrom, A. C. Cytosolic Glucocorticoid Receptor Interaction with Nuclear Factor-Kappa B Proteins in Rat Liver Cells. Biochem. J. 2003, 372, 211-220.
49. Zobel, K.; et al. Design, Synthesis, and Biological Activity of a Potent Smac Mimetic That Sensitizes Cancer Cells to Apoptosis by Antagonizing Iaps. ACS Chem, Biol. 2006, 1 (8), 525-533.
50. Enyedy, I. J.; et al. Discovery of Small-Molecule Inhibitors of Bcl-2 Through Structure-Based Computer Screening. J. Med. Chem. 2001, 44, 4313-4324.
51. Tzung, S.-P.; et al. Antimycin A Mimics a Cell-Death-Inducing Bcl-2 Homology Domain 3. Nat. Cell Biol. 2001, 3, 183-191.
52. Anderson, E. M.; et al. Gene Profiling Study of G3139- and Bcl-2Targeting Sirnas Identifies a Unique G3139 Molecular Signature, Cancer Gene Ther. 2006, 13, 406-414.
53. Winnicka, K.; Bielawski, K.; Bielawska, A. Cardiac Glycosides in Cancer Research and Cancer Therapy. Acta Pol. Pharm. 2006, 63 (2), 109-115.
54. Warren, G. L.; et al. A Critical Assessment of Docking Programs and Scoring Functions. J. Med, Chem. 2006, 49, 5912-5931.
55. Jacobsson, M.; Karlen, A. Ligand Bias of Scoring Functions in Structure-Based Virtual Screening. J. Chem. Inf. Model. 2006, 46 (3), 1334-1343.
56. Alonso, H.; Bliznyuk, A. A.; Gready, J. E. Combined Docking and Molecular Dynamic Simulations in Drag Design. Med. Res. Rev. 2006, 26 (5), 531-568.
57. 3 Binding Site. J. Med. Chem. 2004, 47, 4178-4187.
58. Rapp, C. S.; Schonbrun, C.; Jacobson, M. P.; Kalyanaraman, C.; Huang, N. Automated site preparation in physics-based rescoring of receptor ligand complexes. Proteins 2009, 77, 52-61.